Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease
Status:
Withdrawn
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Chronic graft-versus-host disease (GvHD) is a severe, life threatening complication from
getting a bone marrow or stem cell transplant. It is caused by certain cells from the donor
that attack your cells. The usual treatments, prednisone and cyclosporine, don't work very
well in chronic GVHD.
This research is being done to determine if the combination of the chemotherapeutic and
immunosuppressive, drugs pentostatin, cyclophosphamide and the monoclonal antibody rituximab,
used as in the "PCR" combination will prove useful in the treatment of certain patients with
chronic GvHD (namely those who are unlikely to respond to standard therapy).